Integrating new cellular therapies
Prof Stephen Ansell (Rochester, USA) discusses how the new cellular technologies are being integrated into standard practice.Written by Esther Drain.
Prof Stephen Ansell (Rochester, USA) discusses how the new cellular technologies are being integrated into standard practice.Written by Esther Drain.
The first CAR T-cell treatment was administered in 2010 but the field has developed rapidly since then and in the first quarter of 2018 more than 100 trials… read more.
Checkmate 205, Cohort D. The results of the two-year, post-treatment follow-up of the Checkmate 205, Cohort D study group suggests that nivolumab followed by nivolumab + AVD could… read more.
Although early stage HL patients have an outstanding result, according to Prof Stephen Ansell (Rochester, USA), he argues that those with stage 3 and 4 disease don’t do nearly as… read more.
Prof Peter Johnson (Southampton, UK) discusses where there is consensus and controversy in the management of HL in 2019, as well as talking about the key takeaways from his… read more.
Professor Andrew Davies (Southampton, UK) discussed his presentation on double hit lymphoma. Written by Christine Clark.
Prof Andy Davies (Southampton, UK) discusses 2 important abstracts presented in the plenary session at ICML looking at whether there was a benefit to adding lenalidomide to RCHOP for… read more.
To give you a flavour of key recent advances in the management of lymphoma we asked in this video a group of experts at ICML this summer what… read more.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of ALK-positive NSCLC is now well-established. Professor Ross Camidge (University of Colorado Cancer Centre, Denver, USA) described the lessons that… read more.
Tesaro has submitted a supplemental New Drug Application (sNDA) to the FDA for Zejula (niraparib). The application was granted priority review and has an action date of 24 October 2019.
Dr Popat gives an update of the ongoing studies in mesothelioma in the UK
Professor Ahmed gives an overview of one of the sessions in the BTOG Translational Oncology Symposium.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.